Concordance between Patients and Clinicians for Reporting Symptoms Associated with Treatment for Chronic Hepatitis C during a Pragmatic Clinical Trial

Table 2

Prediction of concordance between patient-reported and clinician-recorded adverse events via logistic regression models selected by LASSO estimation.

	Fatigue	Headache	Nausea/vomiting
	Odds ratio (95% CI)	Odds ratio (95% CI)	Odds ratio (95% CI)
Age
In 10-year units	—	1.36 (1.21, 1.52)	1.37 (1.18, 1.55)
Sex
Female vs. male	—	—	0.59 (0.45, 0.77)
Psychiatric comorbidities
Yes vs. no	—	—	0.64 (0.48, 0.85)
Medical comorbidities
3 or 4 vs. ≤2	—	—	0.58 (0.41, 0.82)
≥5 vs. ≤2	—	—	0.61 (0.41, 0.90)
Insurance type
Uninsured vs. private	—	1.32 (0.71, 2.46)	0.83 (0.44, 1.59)
Other vs. private	—	0.95 (0.35, 2.57)	0.64 (0.23, 1.81)
Medicare vs. private	—	0.82 (0.57, 1.20)	0.98 (0.65, 1.49)
Medicaid vs. private	—	0.75 (0.56, 0.99)	0.81 (0.59,1.11)
Treatment regimen
LDV/SOF vs. EBR/GZR	—	—	1.18 (0.86, 1.62)
PrOD vs. EBR/GZR	—	—	1.07 (0.71, 1.62)

Note: each of the three dichotomous outcome variables indicates presence/absence of concordance between patient and clinician reports. Predictor variables examined included patient age, sex, race, ethnicity, BMI, insurance type, medical comorbidities, cirrhosis status, psychiatric comorbidities, treatment regimen, ribavirin use, and SVR status. Empty cells represent predictor variables that were not selected for inclusion in the LASSO logistic regression model. Abbreviations: CI: confidence interval; LASSO: least absolute shrinkage and selection operator; PrOD: paritaprevir/ritonavir/ombitasvir + dasabuvir (Viekira Pak/Viekira XR™); EBR/GZR: elbasvir/grazoprevir (Zepatier™); LDV/SOF: ledipasvir/sofosbuvir (Harvoni®).